Entering text into the input field will update the search result below

Neuroscience Antibodies Market Development And Business Intelligence

Feb. 23, 2021 7:40 AM ET
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.


  • Major factors influencing the growth of the market.
  • Leading players & Top Segments.
  • Geographic Overview.

Market growth influenced due to following factors-

  • Rising incidence of neurological diseases.
  • Increasing investments in neuroscience research.
  • Growth in the pharmaceutical and biotechnology industries.

Global market size-

According to research report the Neuroscience Antibodies Market is expected to reach $4.18 Billion by 2023, at a CAGR of 10.2%. 

Leading Players-

The neuroscience antibodies market is fragmented, with the presence of several large as well as emerging players. In 2017, Thermo Fisher Scientific (US), Abcam (UK), Bio-Rad (US), and Merck KGaA (Germany) were the leading players in the neuroscience antibodies market. Other major players include BioLegend (US), Cell Signaling Technology (US), F. Hoffmann-La Roche (Switzerland), GenScript (CHINA), Rockland Immunochemicals (US), Santa Cruz Biotechnology (US), Siemens (Germany), and Tecan (Switzerland).

Top Market Segments-

Based on technology, the neuroscience antibodies market is segmented into immunoassays/immunochemistry, molecular diagnostics, clinical chemistry, and other technologies. In 2018, immunoassays/immunochemistry segment is expected to account for the largest share of the neuroscience antibodies and assays market. 

Based on application, the neuroscience antibodies and assays market is segmented into research, drug discovery and development, and in vitro diagnostics. The in vitro diagnostics applications segment is expected to register the highest CAGR during the forecast period.

For Details, Download PDF Brochure Here

Geographic Overview -

In 2018, North America is expected to dominate the market followed by Europe. The large share of this geographical segment is attributed to the increasing investments for the development of structure-based drug designs, growing research in the field of genomics and proteomics, rising demand for high-quality research tools for data reproducibility, and the focus of stakeholders on research projects involving proteins, associated biomolecules, and genes.


Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.